Value of TTF-1 expression in non-squamous non-small-cell lung cancer for assessing docetaxel monotherapy after chemotherapy failure.
cytotoxic chemotherapy
docetaxel
non-squamous non-small-cell lung cancer
second-line chemotherapy
thyroid transcription factor-1
Journal
Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
27
11
2019
accepted:
26
05
2020
entrez:
6
8
2020
pubmed:
6
8
2020
medline:
6
8
2020
Statut:
ppublish
Résumé
Docetaxel is one of the standard second/third-line treatments for non-small-cell lung cancer (NSCLC) following a failed response to prior cytotoxic chemotherapy. The predictive biomarker for the effectiveness of docetaxel therapy remains undetermined. However, thyroid transcription factor-1 (TTF-1) is known to be a good prognostic factor for a variety of chemotherapies. To investigate the association between TTF-1 expression and docetaxel monotherapy outcome, 82 patients with non-squamous NSCLC who received second/third-line docetaxel monotherapy were retrospectively screened. All backgrounds were well-balanced whether or not tumor TTF-1 was expressed, and the present clinical outcomes were similar to those reported by previous clinical studies. A better clinical outcome was indicated in TTF-1 positive compared with TTF-1 negative patients, with disease control rates of 69% vs. 42%, respectively (P=0.03) and median overall survival of 393 days vs. 221.5 days, respectively (P<0.01). Furthermore, progression free survival tended to be longer in TTF-1 positive compared with TTF-1 negative patients (median, 100 days vs. 67 days; P=0.09). Multivariate analysis revealed that TTF-1 positivity was a unique significant predictor for assessing overall survival after docetaxel monotherapy. TTF-1 positivity may be useful for predicting survival outcome in patients who received docetaxel monotherapy after failure of prior chemotherapy.
Identifiants
pubmed: 32754323
doi: 10.3892/mco.2020.2080
pii: MCO-0-0-02080
pmc: PMC7391830
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9Informations de copyright
Copyright © 2020, Spandidos Publications.
Références
Pathol Oncol Res. 2017 Jul;23(3):607-614
pubmed: 27988838
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Lancet Oncol. 2015 Dec;16(16):1630-8
pubmed: 26522337
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
J Clin Oncol. 2000 Jun;18(12):2354-62
pubmed: 10856094
J Thorac Oncol. 2012 Feb;7(2):281-90
pubmed: 22071786
Lancet. 2014 Aug 23;384(9944):665-73
pubmed: 24933332
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Anticancer Res. 2017 Sep;37(9):5125-5131
pubmed: 28870944
Am J Surg Pathol. 2005 May;29(5):633-9
pubmed: 15832087
J Clin Oncol. 2004 Jan 15;22(2):254-61
pubmed: 14722033
J Clin Oncol. 2004 May 1;22(9):1589-97
pubmed: 15117980
J Thorac Oncol. 2013 Oct;8(10):1255-64
pubmed: 24457236
J Clin Oncol. 2010 Jul 10;28(20):3299-306
pubmed: 20530281
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Cancer Res. 2007 Jul 1;67(13):6007-11
pubmed: 17616654
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Chest. 2012 Feb;141(2):420-428
pubmed: 21799026
Biochim Biophys Acta. 2001;1471(2):O1-9
pubmed: 11342188
Lung Cancer. 2014 Jun;84(3):281-8
pubmed: 24725383
Clin Transl Oncol. 2016 Jan;18(1):33-9
pubmed: 26148901
Am J Clin Pathol. 2013 Feb;139(2):160-6
pubmed: 23355200
Anticancer Res. 2018 Sep;38(9):5489-5495
pubmed: 30194207
J Clin Oncol. 2006 Apr 10;24(11):1679-88
pubmed: 16549822
J Cancer Res Clin Oncol. 2015 Jul;141(7):1189-94
pubmed: 25504507
J Thorac Oncol. 2018 Aug;13(8):1138-1145
pubmed: 29874546
Clin Sci (Lond). 2009 Jan;116(1):27-35
pubmed: 19037882
Mol Cancer Ther. 2005 Dec;4(12):2001-7
pubmed: 16373715